Highest-materiality recent filing
BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements
CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
Entered $1,000,000 revolving loan agreement with Bowery Group LLC at 12% interest, 16% default rate, 1-year maturity.
CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired
Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement
Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
BioRestorative Therapies restates financials due to warrant classification error; no cash impact
Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting
Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.
BioRestorative raises $8.1M via warrant exercise and new private placement warrants
Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.
BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease
Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share
Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger
Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.
BioRestorative closes $23M public offering, swaps $10M notes for equity
Closed underwritten public offering of 2.3M units at $10 each, gross proceeds ~$23M. Each unit: 1 common share + 1 warrant.
Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
Exchanged aggregate $9,246,897 principal of convertible notes and warrants for units in proposed public offering.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
Effective November 4, 2021, David Rosa was elected a director of the Company.
Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.
Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.
Max materiality 0.85 · Median 0.50 · Most common event other_material